BridgeBio Explores Phase 3 Acoramidis Data in Depth

August 29, 2023

Bristol Myers Squibb Launches Sotyktu Initiative to Provide a ‘Comprehensive Insight’ into Living with Psoriasis

August 8, 2023

Taiho spends $400 million with a Swiss partner to “turbocharge” three ADCs to the clinic

March 20, 2025

Must Read

Phase 3 of Neurocrine’s Ingrezza cerebral palsy trial unsuccessful

January 3, 2026

Samsung Biologics to Shell Out $280M to Acquire GSK’s U.S. Plant

January 3, 2026

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

January 3, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Merck Gets $700M Funding From Blackstone For Cancer Therapy R&D

Pfizer to Withdraw Vyndaqel in the U.S. Before Patent Expiration in 2028

Roche Ends Development of Obesity Candidate CT-173 and Discontinues Multiple Early-Stage Programs

$20 Million Pediatric CRISPR Center Launched to Develop Treatments for Rare Genetic Diseases

Phase 3 of Neurocrine’s Ingrezza cerebral palsy trial unsuccessful

Patient Death Reported in Long-Term Study of Pfizer’s Hemophilia Therapy Hympavzi

Breyanzi Receives FDA Approval for Marginal Zone Lymphoma

Wave Life Sciences Reports Interim Phase 1 Results for WVE-007 in Obesity Study

Samsung Biologics to Shell Out $280M to Acquire GSK’s U.S. Plant

Triana Biomedicines Secures $120 Million Series B to Advance Lead Molecular Glue Degrader

Crescent Boosts Pipeline with Kelun Deal Worth $80M

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Reg impact assessment next in GenAI’s sights, experts claim

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

Improving life science R&D outcomes with AI

The medical device sector’s surging regulatory burden: how are suppliers coping?

Editor Picks

BridgeBio Explores Phase 3 Acoramidis Data in Depth

Bristol Myers Squibb Launches Sotyktu Initiative to Provide a ‘Comprehensive Insight’ into Living with Psoriasis

Taiho spends $400 million with a Swiss partner to “turbocharge” three ADCs to the clinic

Must Read

Phase 3 of Neurocrine’s Ingrezza cerebral palsy trial unsuccessful

Samsung Biologics to Shell Out $280M to Acquire GSK’s U.S. Plant

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Hot Topics

About Us

Follow Us

Newsletter

Editor Picks

Must Read

Hot Topics

About Us

Follow Us